Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2008

Codexis Opens Fermentation Facility in Budapest

  • Codexis will be opening Codexis Laboratories Hungary Kft (CLH) in Budapest. The site will concentrate on fermentation strain development and process technology. CLH will be an expansion of the company’s existing R&D operations in the U.S., Germany, and Singapore.

    Ronen Tchelet, Ph.D., Codexis’ vp and gm, will head the laboratory. His background is in molecular biology, and he is experienced in strain and technology improvement for industrial fermentation processes.

    “The opening of a new facility in Central Europe is an important addition to our worldwide research organization,” notes Alan Shaw, Ph.D., president and CEO. “Our goal is to advance the development of new industrial fermentation processes, combining Codexis’ proprietary directed evolution technologies and extensive experience with commercial fermentation process development.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »